ada25预览我们对覆盖范围和10多家关键公司的预期

Roger Song, MD, CFA * | Equity Analyst(617) 342-7955 | rsong@jefferies.comFiona Jia, Ph.D. * | Equity Associate+1 (617) 342-7942 | fjia@jefferies.comLiang Cheng, Ph.D. * | Equity Associate+1 (617) 342-7896 | lcheng1@jefferies.comCha Cha Yang, MS, MBA * | Equity Associate+1 (857) 330-5772 | cyang2@jefferies.com RGT-075#785-PPh2a 12W obesity full data. Topline showed 5% pbo-adj WL, some color on AE(4% d/c)/ biomarkers without details. We'll likely see full data including baseline/ WL/ GI-AE.Non-incretin comps:Amycretin#2002-LBPh1b/2a amycretin subq 36W data. Topline in Jan'25 showed 24% pbo-adjWL. We'll likely see full data including baseline/ detailed WL/ GI-AE.GUBamy#857-PPh1 SAD data. GUBamy previously reported Ph1 SAD/ interim MAD data whichshowed 9.76% pbo-adj WL at 6W/ 11d half life. ADA data will likely be full SAD data includingbaseline/ WL/ PK/ GI-AE at 6W.ASC47#847-PPreclinical sema combo data. ASC47 recently had topline Ph1b showing up to 1.7%pbo-adj WL w/ single SC at 50d. ADA poster will likely show WL from ASC47 + sema combo vs.sema in DIO.AZD6234#88-ORPreclinical sema combo data in DIO model. This will be first look of AZD6234preclinical profile, likely include WL from amylin + sema combo in DIO and potentially PK.MET-233#894-PPreclinical profile/ first look of amylin. This will be first look of MET233 preclinicalprofile, likely include WL from amylin mono/ combo with '097 in DIO.Chart 1 - Selective Clinical Incretin Poster/Oral/Symposium at ADA25.Source: ADA25Please see important disclosure information on pages 7 - 12 of this report.This report is intended for Jefferies clients only. Unauthorized distribution is prohibited. Chart 2 - Selective Preclinical Incretin Poster/Oral/Symposium at ADA25.Source: ADA25Chart 3 - Selective Clinical Non-incretin Poster/Oral/Symposium at ADA25.Source: ADA25Please see important disclosure information on pages 7 - 12 of this report.This report is intended for Jefferies clients only. Unauthorized distribution is prohibited. Chart 4 - Selective Preclinical Non-incretin Poster/Oral/Symposium at ADA25.Source: ADA25Chart 5 - Selective Poster/Oral/Symposium on T1D at ADA25.Source: ADA25Please see important disclosure information on pages 7 - 12 of this report.This report is intended for Jefferies clients only. Unauthorized distribution is prohibited. Chart 6 - Ph3 ACHIEVE-1 orfo topline data.Source: Company reportChart 7 - Ph2 MariTide WL in Non-diabetic Obesity.Source: Company reportChart 8 - Ph2 MariTide WL in Diabetic Obesity.Source: Company reportPlease see important disclosure information on pages 7 - 12 of this report.This report is intended for Jefferies clients only. Unauthorized distribution is prohibited. Chart 9 - Ph1a oral ASC30 GI-AE.Source: Company reportPlease see important disclosure information on pages 7 - 12 of this report.This report is intended for Jefferies clients only. Unauthorized distribution is prohibited. Company Valuation/RisksFor Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action or call 212.284.2300.Analyst Certification:I, Roger Song, MD, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) andsubject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or viewsexpressed in this research report.I, Fiona Jia, Ph.D., certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subjectcompany(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressedin this research report.I, Liang Cheng, Ph.D., certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) andsubject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or viewsexpressed in this research report.I, Cha Cha Yang, MS, MBA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies)and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations orviews expressed in this research report.As is the case with all Jefferies employees, the analyst(s) responsible for the coverage of the financial instruments discussed in this report receives compensationbased in part on the overall performance of the firm, including investment banking income. We seek to update our research as appropriate, but various regulationsmay prevent us from doing so. Aside from certain industry reports published on a periodic